BioNTech reported first-quarter 2025 revenues of €182.8 million, a slight decrease from €187.6 million in the same quarter of 2024. The company posted a net loss of €415.8 million, widening from a €315.1 million loss the previous year, primarily due to increased R&D expenses, which rose to €525.6 million.
Despite the loss, BioNTech maintains a strong cash position of €15.9 billion, comprising €10.2 billion in cash and cash equivalents, €3.5 billion in current security investments, and €2.1 billion in non-current security investments. GlobeNewswire
The company reaffirmed its full-year 2025 revenue guidance of €1.7–€2.2 billion, anticipating that revenues will be concentrated in the latter part of the year, consistent with seasonal COVID-19 vaccination patterns.
BioNTech continues to focus on advancing its oncology pipeline, with significant investments in antibody-drug conjugates (ADCs) and other antibody-based therapies. The company also completed the acquisition of Biotheus, securing full global rights to BNT327, further strengthening its oncology portfolio. michael-burry.com